Press Releases

Month Year

Month Year

Oct 22, 2021

Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease

Pivotal trial met primary and all key secondary endpoints
Oct 20, 2021

FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Oct 7, 2021

Positive results from the first study of high-dose quadrivalent influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations

First study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
Sep 28, 2021

New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection

Presentations focused on respiratory syncytial virus, meningococcal disease, and influenza
Sep 19, 2021

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

*Phase 3 trial met its primary and key secondary endpoints

Show per page

Print
Email page
RSS